[{"Assets_0_Q2_USD":372023000.0,"EarningsPerShareBasic_2_Q2_USD":0.48,"EarningsPerShareBasic_1_Q2_USD":0.33,"EarningsPerShareDiluted_2_Q2_USD":0.46,"EarningsPerShareDiluted_1_Q2_USD":0.3,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":50400000.0,"StockholdersEquity_0_Q2_USD":-296729000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":120317000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":120463000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":107468000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":107614000.0,"Ticker":"INVA","CIK":"1080014","name":"INNOVIVA, INC.","OfficialName":"Innoviva Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1257937389.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170808"}]